Analysts predict biopharma gains as Democrats take Congress control

Analysts say the biopharma sector is set to benefit from the recent shift in U.S. Congress, with Democrats now holding majorities in both the House and Senate.

They note that drug‑pricing debates are likely to recede, as both the current and previous administrations have already put pricing controls in place.

The Biden‑era Inflation Reduction Act automatically expands the list of drugs subject to Medicare price negotiations each year, a mechanism Democrats view as a lasting victory that is difficult to overturn.

With fewer political headwinds expected, the industry’s broader recovery is projected to accelerate.